Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
None
A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

-treatment with icosapent ethyl (IPE), also known as Vascepa, compared to usual standard of care to prevent and reduce the sequelae of laboratory-confirmed viral upper respiratory infection (URI)-related

percutaneous coronary intervention
coronavirus infection
serologic test
myocardial infarction
influenza
  • 0 views
  • 18 Sep, 2021
  • 1 location
None
The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk

stable statin therapy will be randomized (1:1) to receive either icosapent ethyl (IPE) 2g BID or standard of care. It is hypothesized that assignment to IPE will lower progenitor cell depletion as

hypertension
stroke
stenosis
diabetes
acute coronary syndrome
  • 25 views
  • 02 Oct, 2021
  • 4 locations
None
EPA for Metastasis Trial 2

larger study which will recruit 448 men and women with liver metastases from bowel cancer. Trial participants will receive either Icosapent Ethyl (pure EPA derived from fish oil) or placebo (dummy

cancer
liver surgery
liver metastasis
hepatectomy
metastasis
  • 94 views
  • 09 Aug, 2021
  • 12 locations
None
PRevention Using EPA Against coloREctal Cancer

This research study is evaluating the effect of AMR101 as a possible chemopreventive agent to reduce risk of colorectal cancer in individuals with a history of colorectal adenoma. The name of the study drug involved in this study is: -- AMR101 (VASCEPA).

  • 0 views
  • 03 May, 2021
  • 1 location